ASTX
Tradr 2X Long ASTS Daily ETF
$14.75
$-0.69 (-4.47%)
Real-time · Aug 14, 2026 1:02 PM ET
Key Statistics
Net Assets (AUM)
$1.40B
Expense Ratio
See prospectus
Previous Close
$15.44
Day Range
$14.25 – $16.06
52-Week Range
$8.80 – $114.18
Volume
2.32M
Avg Vol (50D)
-
Beta
-18.60
Historical Performance
1M
-4.04%
3M
-50.18%
6M
-62.97%
YTD
-62.27%
1Y
-49.61%
3Y
—
5Y
—
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
CFD AST SPACEMOBILE INC
7.02%
CFD AST SPACEMOBILE INC
-13.35%
Top 2 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →
ASTX News
- Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board
- Roche pens $490m Astex breast cancer license deal
- Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
- Racura Oncology Announces Auckland Investor Briefing and Presentation at 20th Bioshares Biotech Summit in August 2026
- Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
- Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development
- Honours for air ambulance staff and foster carers
- T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight
- Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
- Tradr 2X Long ASTS Daily ETF (BATS:ASTX) Short Interest Down 49.1% in April
Data for ASTX is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.